<span item_type="fundamental" item_id="95d4ae7442b4ee10c5631f1b54f1ee4b" counter_id="ST/US/BTAI" env="prod"></span><span item_type="announcement" item_id="581965436482815361" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 98 K, missing the estimate of USD 216.67 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.18, missing the estimate of USD -1.34.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -9.619 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Product Revenue, Net</strong>: $98,000 for the three months ended September 30, 2025, compared to $214,000 for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $386,000, compared to $1,900,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $30,911,000 for the three months ended September 30, 2025, compared to $13,650,000 for the same period in 2024. For the nine months ended September 30, 2025, net loss was $57,352,000, compared to $48,740,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: $8,740,000 for the three months ended September 30, 2025, compared to $5,101,000 for the same period in 2024. For the nine months ended September 30, 2025, R&amp;D expenses were $23,550,000, compared to $24,534,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: $5,381,000 for the three months ended September 30, 2025, compared to $7,683,000 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $16,689,000, compared to $30,398,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $43,405,000 for the nine months ended September 30, 2025, compared to - $57,218,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $50,871,000 for the nine months ended September 30, 2025, compared to $32,384,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cost of Goods Sold</strong>: $11,000 for the three months ended September 30, 2025, compared to $1,170,000 for the same period in 2024. For the nine months ended September 30, 2025, cost of goods sold was $132,000, compared to $1,311,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to submit a supplemental New Drug Application (sNDA) for label expansion of IGALMI® in the at-home setting in early first quarter of 2026, based on the successful SERENITY At-Home trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has paused further development of its AI platform and certain immuno-oncology programs, focusing resources on core clinical programs and commercialization efforts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm"></span></li></ul>

Bioxcel Therap | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 98 K